ISSN:
1573-0646
Keywords:
lonidamine
;
breast cancer
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00198600
Permalink